Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Otonomy Inc (OTIC)

Otonomy Inc (OTIC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 582
  • Shares Outstanding, K 68,527
  • Annual Sales, $ 130 K
  • Annual Income, $ -51,180 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.02
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.37
  • Most Recent Earnings $-0.18 on 11/10/22
  • Next Earnings Date 05/08/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0075 +13.33%
on 04/11/23
0.1169 -92.73%
on 03/29/23
-0.1000 (-92.17%)
since 03/10/23
3-Month
0.0075 +13.33%
on 04/11/23
0.1250 -93.20%
on 01/24/23
-0.0885 (-91.24%)
since 01/11/23
52-Week
0.0075 +13.33%
on 04/11/23
2.5400 -99.67%
on 04/20/22
-2.1715 (-99.61%)
since 04/11/22

Most Recent Stories

More News
Otonomy: Q3 Earnings Snapshot

Otonomy: Q3 Earnings Snapshot

OTIC : 0.0085 (-92.64%)
Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus

OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints across all timepointsCompany to discontinue...

OTIC : 0.0085 (-92.64%)
Otonomy (OTIC) Q2 2022 Earnings Call Transcript

OTIC earnings call for the period ending June 30, 2022.

OTIC : 0.0085 (-92.64%)
Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and...

OTIC : 0.0085 (-92.64%)
Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update

SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative...

OTIC : 0.0085 (-92.64%)
Otonomy to Participate in the H.C. Wainwright Global Investment Conference

SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative...

OTIC : 0.0085 (-92.64%)
Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative...

OTIC : 0.0085 (-92.64%)
Otonomy (OTIC) Q1 2022 Earnings Call Transcript

OTIC earnings call for the period ending March 31, 2022.

OTIC : 0.0085 (-92.64%)
Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update

Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluationOTO-313 Phase 2 trial in tinnitus...

OTIC : 0.0085 (-92.64%)
Otonomy to Report First Quarter 2022 Financial Results and Provide Corporate Update

SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative...

OTIC : 0.0085 (-92.64%)

Business Summary

Otonomy, Inc. engages in developing and commercializing therapeutics to address unmet medical needs in the otology market. It develops therapeutics for treatment of inner and middle ear disorders. The Company's product candidates under development includes AuriPro to treat pediatric patients with middle...

See More

Key Turning Points

3rd Resistance Point 0.0290
2nd Resistance Point 0.0245
1st Resistance Point 0.0165
Last Price 0.0085
1st Support Level 0.0040
2nd Support Level N/A
3rd Support Level N/A

See More

52-Week High 2.5400
Fibonacci 61.8% 1.5726
Fibonacci 50% 1.2737
Fibonacci 38.2% 0.9749
Last Price 0.0085
52-Week Low 0.0075

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar